Lizard-Nacol S, Arnould L, Riedinger J M, Arnal M, Collin F, Guerrin J
Centre Georges-François-Leclerc, Dijon, France.
Bull Cancer. 1994 Sep;81(9):780-4.
Amplification of c-myc and c-erb beta-2 (HER-2/neu) proto-oncogenes were analyzed in breast cancer tissues obtained from 100 patients without lymph node involvement (N-). An amplification of the c-myc gene was detected in four cases and a c-erb beta-2 (HER-2/neu) amplification in eight cases. The frequency of these abnormalities were compared to classical prognostic parameters as well as to new biological prognostic markers (cellular cycle, cathepsin-D and pS2 protein). Most of altered tumors were associated to some classical poor prognostic factors such as: steroid receptor-negative tumors, poorly differentiated tumors, high histoprognostic grade and tumor cell density. In contrast, no relation was found with new biological parameters. The analyses of these data in relation to clinical evolution will be of interest to evaluate their prognostic value.
对100例无淋巴结转移(N-)的乳腺癌患者的组织样本进行了c-myc和c-erb beta-2(HER-2/neu)原癌基因的扩增分析。在4例患者中检测到c-myc基因扩增,8例患者检测到c-erb beta-2(HER-2/neu)扩增。将这些异常的频率与经典预后参数以及新的生物学预后标志物(细胞周期、组织蛋白酶-D和pS2蛋白)进行了比较。大多数发生改变的肿瘤与一些经典的不良预后因素相关,如:类固醇受体阴性肿瘤、低分化肿瘤、高组织预后分级和肿瘤细胞密度。相反,未发现与新的生物学参数有相关性。分析这些数据与临床进展的关系,将有助于评估它们的预后价值。